Navigation Links
Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
Date:5/8/2008

y patient diaries during the treatment periods using the Brief Pain Inventory (BPI); and pre- and post-treatment scores using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index of pain, stiffness and function. Plasma levels were evaluated for morphine sulfate and naltrexone pre-dose and at specified intervals up to 12 hours post-dose on days seven and 14 of the treatment periods, and at the end of the study. Follow-up calls with patients a further seven days after the end of the study were conducted to assess the occurrence of any adverse events.

During treatment, ALO-01 was similar to extended-release morphine sulfate for mean pain intensity (2.3 to 2.4 at Day 14) and BPI (average 2.1 to 2.2). WOMAC scores were also comparable with composite indices of 24.5 for ALO-01 and 26.6 for extended-release morphine sulfate. Plasma concentrations of morphine were similar over time, and naltrexone levels at the end of each treatment period below a quantifiable limit for most patients (82.1 percent). In patients with detectable levels of naltrexone, there was no impact on pain scores. Adverse events were mostly mild to moderate, and included constipation (15.5 percent and 12.7 percent), nausea and somnolence (both 9.9 percent and 8.5 percent) for ALO-01 and extended-release morphine sulfate, respectively.

Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other important potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2007.

About Alpharma

Alpharma Inc. (NYSE: '/>"/>

SOURCE Alpharma Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
2. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
3. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
4. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research
5. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
6. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
9. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
10. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
11. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)...  In an effort to raise awareness and the ... DentaQuest established the Health Equity Hero Awards to celebrate ... More than 83 million people in ... care. These barriers are most significant for those who ... language, health literacy or geographic isolation.   "Connecting ...
(Date:5/4/2015)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... company as Vice President, Medical Affairs. ... Aurora to the Neurocrine team as our Vice ... and Chief Executive Officer of Neurocrine Biosciences. "Bill,s experience ... with his extensive network and influence with psychiatric and ...
(Date:5/4/2015)... 2015 Microbrush International, a leading developer, producer ... restorative procedures, today announced the acquisition of DentiSmart ... sectional matrix system used in dental restorative procedures. ... opportunity to add DentiSmart to our growing portfolio ... VP and General Manager of Microbrush. "DentiSmart,s products ...
Breaking Medicine Technology:DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 2DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 3DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 4Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 2Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 3Microbrush International Announces Acquisition of DentiSmart 2
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... the U.S. and China, commented today on the ruling this ... from funding research involving human embryonic stem cells.  In issuing ... first passed in 1996 prohibiting federal money for research where ...
... KemPharm, Inc. announced today that it has received a ... Trademark Office (USPTO) for its patent application entitled "Non-Standard ... and Using the Same", U.S. Patent No. 7,776,917 B2. ... No. 7,772,222, provides broad protection of the Company,s Ligand ...
Cached Medicine Technology:NeoStem Comments on Recent Court Ruling Blocking the Federal Government's Funding of Embryonic Stem Cell Research 2NeoStem Comments on Recent Court Ruling Blocking the Federal Government's Funding of Embryonic Stem Cell Research 3KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 2KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 3
(Date:5/4/2015)... New Jersey (PRWEB) May 04, 2015 Parlin ... to give a chance to more youths to participate and ... encourage youths in her area to do good deeds and ... Dr.Blagoev intends to empower their minds and teach them to ... contest is accessible to any youth 18 years of age ...
(Date:5/4/2015)... May 05, 2015 The ... Irene Taylor , Volunteer Executive Director of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor," said NAPW President Star Jones. "Her ...
(Date:5/4/2015)... May 05, 2015 The National ... Weis as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in healthcare. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
Solid 14 mm blades. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Speculum with malleable plate to support flap during ablation of thestromal bed....
Medicine Products: